Literature DB >> 10942474

Two-stage cervical cancer screening: an alternative for resource-poor settings.

L Denny1, L Kuhn, L Risi, R M Richart, A Pollack, A Lorincz, F Kostecki, T C Wright.   

Abstract

OBJECTIVE: We sought to introduce 2-stage cervical cancer screening in which 2 screening tests are performed sequentially (the second test is performed only if the first result is positive), followed by treatment if both test results are abnormal. STUDY
DESIGN: A total of 1423 women from Cape Town, South Africa, were screened by direct visual inspection, human papillomavirus deoxyribonucleic acid testing, cytologic testing, and cervicography. If an abnormality was identified with any test, women were referred for colposcopy.
RESULTS: Direct visual inspection, cytologic testing, human papillomavirus deoxyribonucleic acid testing, and cervicography, when used alone, identified 24, 26, 23, and 23 cases of disease (high-grade squamous intraepithelial lesion or cancer) per 1000 women, respectively, and would classify 182, 71, 137, and 112 women without disease as having abnormal results. Two-stage screening with direct visual inspection first, followed by cytologic testing, human papillomavirus deoxyribonucleic acid testing, or cervicography, would detect 18, 16, and 18 cases per 1000 women, respectively, and would substantially reduce the number of women without disease who were classified as having abnormal results.
CONCLUSION: Two-stage screening for cervical cancer provides an attractive alternative to conventional screening for low-resource settings.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Biology; Cancer; Cervical Cancer; Cervix; Clinical Research; Developing Countries; Diseases; English Speaking Africa; Examinations And Diagnoses; Genitalia; Genitalia, Female; Laboratory Examinations And Diagnoses; Neoplasms; Physiology; Research Methodology; Research Report; Screening; South Africa; Southern Africa; Urogenital System; Uterus

Mesh:

Substances:

Year:  2000        PMID: 10942474     DOI: 10.1067/mob.2000.105871

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  Two-stage screening for early dementia in primary care.

Authors:  Ellen Grober; Wenzhu Bi Mowrey; Amy R Ehrlich; Peter Mabie; Steven Hahn; Richard B Lipton
Journal:  J Clin Exp Neuropsychol       Date:  2016-06-07       Impact factor: 2.475

2.  Neuropsychological strategies for detecting early dementia.

Authors:  Ellen Grober; Charles Hall; Maryanne McGinn; Toni Nicholls; Stephanie Stanford; Amy Ehrlich; Laurie G Jacobs; Gary Kennedy; Amy Sanders; Richard B Lipton
Journal:  J Int Neuropsychol Soc       Date:  2008-01       Impact factor: 2.892

3.  The costs of reducing loss to follow-up in South African cervical cancer screening.

Authors:  Jeremy D Goldhaber-Fiebert; Lynette E Denny; Michelle De Souza; Thomas C Wright; Louise Kuhn; Sue J Goldie
Journal:  Cost Eff Resour Alloc       Date:  2005-11-15

4.  Estimating the cost of cervical cancer screening in five developing countries.

Authors:  Jeremy D Goldhaber-Fiebert; Sue J Goldie
Journal:  Cost Eff Resour Alloc       Date:  2006-08-03

5.  Diagnosing cervical dysplasia using visual inspection of the cervix with acetic acid in a woman in rural Haiti.

Authors:  Elizabeth Roger; Oguchi Nwosu
Journal:  Int J Environ Res Public Health       Date:  2014-11-28       Impact factor: 3.390

6.  Identifying memory impairment and early dementia in primary care.

Authors:  Ellen Grober; Dorothy Wakefield; Amy R Ehrlich; Peter Mabie; Richard B Lipton
Journal:  Alzheimers Dement (Amst)       Date:  2017-02-24

7.  Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus.

Authors:  Rebecca Luckett; Neo Mogowa; Howard J Li; Adrienne Erlinger; Michele R Hacker; Katharine Esselen; Sarah Feldman; Roger Shapiro; Chelsea Morroni; Doreen Ramogola-Masire
Journal:  Obstet Gynecol       Date:  2019-10       Impact factor: 7.661

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.